240 related articles for article (PubMed ID: 34387129)
21. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review.
Wang F; Shi X; Yu X; Yang Y
Front Endocrinol (Lausanne); 2024; 15():1326684. PubMed ID: 38318292
[TBL] [Abstract][Full Text] [Related]
22. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
Kurokawa R; Ota Y; Gonoi W; Hagiwara A; Kurokawa M; Mori H; Maeda E; Amemiya S; Usui Y; Sato N; Nakata Y; Moritani T; Abe O
AJNR Am J Neuroradiol; 2020 Sep; 41(9):1683-1689. PubMed ID: 32763900
[TBL] [Abstract][Full Text] [Related]
23. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
Ducloux R; Tavernier JY; Wojewoda P; Toullet F; Romanet S; Averous V
Ann Endocrinol (Paris); 2021 Feb; 82(1):8-14. PubMed ID: 33290748
[TBL] [Abstract][Full Text] [Related]
24. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review.
Iglesias P; Sánchez JC; Díez JJ
Pituitary; 2021 Aug; 24(4):630-643. PubMed ID: 33761049
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report.
Fujimiya T; Azuma K; Togashi Y; Kuwata K; Unezaki S; Takeuchi H
J Pharm Health Care Sci; 2024 Feb; 10(1):10. PubMed ID: 38365819
[TBL] [Abstract][Full Text] [Related]
26. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
[TBL] [Abstract][Full Text] [Related]
27. A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors.
Yeung SJ; Qdaisat A; Bischof JJ; Caterino JM; Kyriacou DN; Coyne Md C
Am J Emerg Med; 2024 Jun; 80():227.e1-227.e5. PubMed ID: 38705758
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics of programmed cell death-1 inhibitor-associated hypophysitis].
Zhang Y; Wang SC; Zhang Q; Li HY; Liu SS; Wang XH; Liu Y
Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):192-197. PubMed ID: 38326046
[No Abstract] [Full Text] [Related]
29. Isolated Adrenocorticotropic Hormone Deficiency Associated with Severe Hyperkalemia During Pembrolizumab Therapy in a Patient with Ureteral Cancer and an Ileal Conduit: A Case Report and Literature Review.
Hinata Y; Ohara N; Sakurai Y; Koda R; Yoneoka Y; Takada T; Hara N; Nishiyama T
Am J Case Rep; 2021 Jul; 22():e931639. PubMed ID: 34262010
[TBL] [Abstract][Full Text] [Related]
30. A case of Empty Sella syndrome with adrenal insufficiency masked by prednisolone after administration of immune checkpoint inhibitors.
Iwamoto Y; Tatsumi F; Ohnishi M; Katakura Y; Kimura T; Shimoda M; Nakanishi S; Mune T; Kaneto H
Medicine (Baltimore); 2024 Mar; 103(10):e37204. PubMed ID: 38457550
[TBL] [Abstract][Full Text] [Related]
31. Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody.
Urai S; Watanabe M; Bando H; Motomura Y; Yamamoto M; Tachihara M; Kanzawa M; Fukuoka H; Iguchi G; Ogawa W
Front Immunol; 2023; 14():1284301. PubMed ID: 38035072
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.
Nguyen H; Shah K; Waguespack SG; Hu MI; Habra MA; Cabanillas ME; Busaidy NL; Bassett R; Zhou S; Iyer PC; Simmons G; Kaya D; Pitteloud M; Subudhi SK; Diab A; Dadu R
Endocr Relat Cancer; 2021 Jun; 28(7):419-431. PubMed ID: 33890870
[TBL] [Abstract][Full Text] [Related]
33. Two Cases of Atezolizumab-Induced Hypophysitis.
Kanie K; Iguchi G; Bando H; Fujita Y; Odake Y; Yoshida K; Matsumoto R; Fukuoka H; Ogawa W; Takahashi Y
J Endocr Soc; 2018 Jan; 2(1):91-95. PubMed ID: 29362727
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab Induced Hypophysitis in a Patient Allergic to Triamcinolone: An Increasingly Recognized Endocrinopathy Related to Immunotherapy.
Chowdhury RH; Hasan MN
Mymensingh Med J; 2020 Oct; 29(4):1021-1025. PubMed ID: 33116112
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
36. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management.
Kotwal A
Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):427-434. PubMed ID: 34183541
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
[TBL] [Abstract][Full Text] [Related]
38. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
39. Hypopituitarism with secondary adrenocortical insufficiency and arginine vasopressin deficiency due to hypophysitis after COVID-19 vaccination: a case report.
Watanabe S; Tamura Y; Oba K; Kitayama S; Sato M; Kodera R; Toyoshima K; Chiba Y; Araki A
BMC Endocr Disord; 2024 May; 24(1):71. PubMed ID: 38769570
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-mediated hypophysitis: no place like home.
Cooksley T; Knight T; Lindsay D; Gupta A; Ho JH; Higham C; Lorigan P; Adam S
Clin Med (Lond); 2023 Jan; 23(1):81-84. PubMed ID: 36697002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
